Integer (NYSE:ITGR) Stock Rating Lowered by Oppenheimer

Oppenheimer downgraded shares of Integer (NYSE:ITGR) from an outperform rating to a market perform rating in a research note released on Friday, Marketbeat Ratings reports.

ITGR has been the topic of a number of other reports. Piper Sandler reissued an “overweight” rating and issued a $140.00 price target (up from $125.00) on shares of Integer in a report on Friday, October 25th. Citigroup raised their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Wells Fargo & Company reissued an “overweight” rating and issued a $160.00 target price on shares of Integer in a research report on Tuesday, December 3rd. KeyCorp upped their price target on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Finally, Truist Financial upped their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $147.67.

Integer Trading Down 3.9 %

ITGR opened at $129.96 on Friday. The company’s 50 day moving average price is $137.74 and its two-hundred day moving average price is $132.58. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. Integer has a fifty-two week low of $98.63 and a fifty-two week high of $146.36. The firm has a market capitalization of $4.37 billion, a price-to-earnings ratio of 38.68, a PEG ratio of 1.72 and a beta of 1.13.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. As a group, research analysts predict that Integer will post 6.01 earnings per share for the current year.

Hedge Funds Weigh In On Integer

A number of hedge funds and other institutional investors have recently made changes to their positions in ITGR. Blue Trust Inc. raised its stake in Integer by 4.4% in the fourth quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock valued at $220,000 after buying an additional 71 shares during the last quarter. Arizona State Retirement System raised its position in Integer by 0.9% during the fourth quarter. Arizona State Retirement System now owns 9,732 shares of the medical equipment provider’s stock valued at $1,290,000 after acquiring an additional 84 shares in the last quarter. HighTower Advisors LLC raised its position in Integer by 0.8% during the third quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock valued at $1,579,000 after acquiring an additional 90 shares in the last quarter. HighPoint Advisor Group LLC raised its position in Integer by 6.4% during the fourth quarter. HighPoint Advisor Group LLC now owns 1,684 shares of the medical equipment provider’s stock valued at $234,000 after acquiring an additional 101 shares in the last quarter. Finally, Norden Group LLC grew its holdings in Integer by 7.0% in the fourth quarter. Norden Group LLC now owns 1,668 shares of the medical equipment provider’s stock valued at $221,000 after purchasing an additional 109 shares during the period. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.